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  ABSTRACT 
  Objective      The British Society for Rheumatology 
Biologics Register (BSRBR) has collected data on adverse 
events including pregnancies in patients with rheumatoid 
arthritis treated with anti-tumour necrosis factor (anti-
TNF) therapy. The purpose of this report is to summarise 
the pregnancy outcomes in women treated with anti-TNF 
in the BSRBR.   
  Methods      Patients were categorised according to 
anti-TNF exposure as follows: (1) exposure to anti-TNF 
and to methotrexate (MTX) and/or leﬂ  unomide (LEF) at 
conception (n=21 pregnancies); (2) exposure to anti-TNF 
at conception (n=50); (3) exposure to anti-TNF prior to 
conception (n=59); (4) no exposure to anti-TNF (control 
group; n=10).   
  Results      Eighty-eight live births in a total of 130 
pregnancies were reported in patients who received anti-
TNF before or during pregnancy. The rate of spontaneous 
abortion was highest among patients exposed to 
anti-TNF at the time of conception (with MTX/LEF 33% 
and without MTX/LEF 24%). This compared with 17% 
spontaneous abortions in those with prior exposure to 
anti-TNF and 10% spontaneous abortions in the control 
group. Ten terminations were performed.   
  Conclusion      Although the results to date have been 
promising, no ﬁ  rm conclusions can be drawn about the 
safety of anti-TNF during pregnancy and, without further 
evidence, guidelines which suggest these drugs should 
be avoided at the time of conception cannot yet be 
changed.      
  INTRODUCTION 
  Anti-tumour necrosis factor (anti-TNF) therapies 
have been available for the management of arthri-
tis-related diseases for over a decade. The US FDA 
categorises anti-TNF agents as category ‘B’ drugs 
because animal reproduction studies have failed to 
demonstrate a risk to the fetus but adequate and 
well-controlled studies of pregnant women have 
not been conducted.    1    
  To date, information on pregnancies in patients 
exposed to anti-TNF agents has been reassuring, 
with few reports of adverse pregnancy outcomes. 
One exception has been the report by Carter   et al         2    
which listed 61 congenital anomalies reported to 
the FDA in 41 women exposed to anti-TNF agents 
including one child with the VACTERL syndrome 
(a syndrome seen in embryos and fetuses charac-
terised by abnormalities of the vertebrae (V), anus 
(A), cardiovascular tree (C), trachea (T), oesophagus 
(E), renal system (R) and limb buds (L)). However, 
this study lacked a denominator of exposure. 
National registries such as the British Society for 
Rheumatology Biologics Register (BSRBR), which 
collects data on adverse events and pregnancy out-
comes in patients treated with anti-TNF therapy, 
provide a more realistic representation of the effect 
of anti-TNF therapy on pregnancy outcome. Using 
data from the BSRBR, we previously reported on 
32 pregnancies with known outcome in women 
exposed to anti-TNF agents.    3    Since this publica-
tion, the number of pregnancies reported to the 
BSRBR has increased to 130 and the outcome of 
these pregnancies is reviewed in this paper.   
  METHODS 
    Study design and patient population 
  The patients for this study were participants regis-
tered in the BSRBR starting treatment with one of 
the three available anti-TNF therapies (adalimumab 
(ADA), etanercept (ETA) and inﬂ  iximab (INF)). In 
addition to the anti-TNF cohort, a parallel cohort of 
patients with active rheumatoid arthritis (RA) receiv-
ing non-biological disease-  modifying antirheumatic 
drugs (nb-DMARD) has been recruited (guide dis-
ease activity score in 28 joints (DAS28) >4.2).   
  Data  collection 
  Follow-up information is collected from medical 
records every 6 months for the ﬁ  rst 3 years and annu-
ally thereafter. Data at follow-up include any changes 
to antirheumatic treatment, reasons for changes, and 
the onset of any adverse event including pregnan-
cies. In addition, for the ﬁ  rst 3 years of the study, 
patients are asked directly if they have received new 
treatments and about new referrals to (hospital) doc-
tors. Data on pregnancies and pregnancy outcomes 
are also extracted from these patient reports. 
  All reports of pregnancies are followed up with 
an additional questionnaire which includes infor-
mation on exposure to biological agents at the 
time of conception, details of pregnancy outcome 
including live births, spontaneous abortions and 
terminations. Details of pregnancy complications 
are collected as well as any details of congenital 
malformations. For the purpose of this analysis, 
pregnancies were divided into three groups: group I 
(exposure to anti-TNF at conception); group II (past 
exposure to anti-TNF); group III (never exposed to 
anti-TNF). Given the known risk of adverse preg-
nancy outcomes associated with the DMARDs 
methotrexate (MTX) and leﬂ  unomide (LEF), group 
I was further categorised into (a) those exposed to 
MTX and/  or LEF at conception and (b) those not 
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anti-TNF agents were reported. At registration, baseline DAS28 
and Health Assessment Questionnaire (HAQ) scores were sig-
niﬁ  cantly higher in the anti-TNF therapy groups than in the nb-
DMARD group (  table 1  ). For both baseline DAS28 and HAQ 
score, a signiﬁ  cant difference was observed between groups Ia 
and Ib. Patients in group Ia also had a higher HAQ score com-
pared with patients in group II.   
  Pregnancy  outcomes 
  Eighty-eight live births in a total of 130 pregnancies (including 
three pregnancies with twin gestation) in patients exposed to 
anti-TNF therapy were reported: 42/71 (59%) in group I and 
exposed to MTX and/or LEF at conception. Women could have 
been included more than once in the analysis if more than one 
pregnancy had been recorded during the follow-up time and 
each pregnancy was allocated to the appropriate exposure group. 
For descriptive data, the denominator represents the number of 
pregnancies per group, and, therefore, the sum of the percent-
ages presented within each group can be more than 100%.     
  RESULTS 
  Study  population 
  A total of 130 pregnancies in 118 women ever exposed to anti-
TNF agents and 10 pregnancies in 10 women never exposed to 
  Table  1         Overview of pregnancy outcomes in the BSRBR   
 
 Group  Ia: 
anti-TNF therapy+
MTX or LEF at time 
of conception 
 Group  Ib: 
anti-TNF therapy 
but no MTX or LEF at 
time of conception 
 Group  II: 
anti-TNF therapy 
prior to conception 
 Group  III: 
never exposed to 
anti-TNF therapy 
Number  of  women  with  pregnancy         20         44            54      10
Number  of  pregnancies         21         50            59      10
  Single  births         21         49            58       9
  Twins          0          1             1       1
Age,  mean  (SD)         29.7  (8.1)         34.4  (5.2)            32.6  (4.9)      32.5  (5.2)
Baseline  DAS28  score,  n/N*         20/20         40/44            52/54      10/10
  Mean  (SD)          6.5  (0.6)          6.1  (1.2)             6.0  (1.0)       5.1  (1.2)
Baseline HAQ score, n/N†         20/20         41/44            49/54       8/10
  Mean  (SD)          2.2  (0.4)          1.9  (0.5)             1.6  (0.6)       1.0  (0.4)
Diagnosis
  R A         1 6         3 6            4 6      1 0
  P s A          1          2             1       0
  J I A          2          4             4       0
  A S          0          2             1       0
  Adult-onset  Still’s  disease          1          0             1       0
  S L E          0          0             1       0
Anti-TNF therapy at conception
  Inﬂ   iximab          5          4             –       –
  Etanercept         12         36             –       –
  Adalimumab          4         10             –       –
Anti-TNF therapy prior to conception
  Inﬂ   iximab  (INF)          4          2            15       0
  Etanercept  (ETA)          1          1            23       0
  Adalimumab  (ADA)          1          0            11       0
  >1  anti-TNF  agent          1          2            10       0
Conventional DMARD use at conception
  Methotrexate  (MTX)         13          0             0       0
  Leﬂ   unomide  (LEF)          3          0             0       0
  Sulfasalazine  (SSZ)          0          1             4       3
  Hydroxychloroquine  (HCQ)          0          0             1       0
  Azathioprine  (AZA)          0          1             2       0
  IM-gold  (iAU)          0          1             1       0
  Combination of DMARDs       3 (MTX/HCQ) and 
     2  (MTX/SSZ)
         2  
     (SSZ/HCQ)
            1  
         (AZA/SSZ)
      0
Steroid  use  at  conception          6  (29%)         17  (34%)            24  (41%)       3  (30%)
Pregnancy outcome**
  Live  birth         10  (48%)         32  (64%)            46  (78%)‡      10  (100%)§
  Termination          4  (19%)          4  (8%)¶             2  (3%)       0
  Spontaneous  abortion          7  (33%)         12  (24%)            10  (17%)       1  (10%)
  Neonatal  death          0          1  (2%)             0       0
  Intrauterine  death          0          2  (4%)‡             2  (3%)‡       0
Premature delivery (≤36 weeks)          3          8 ‡             8       2
       *DAS28 score signiﬁ  cantly higher in the anti-TNF groups compared with the nb-DMARD group. DAS28 signiﬁ  cantly higher in group Ia compared with group II (p=0.0213, unpaired t test). 
**Since the number of outcomes is divided by the number of pregnancies, the total sum of percentages can be more than 100%
  †HAQ score signiﬁ  cantly higher in the anti-TNF groups compared with the nb-DMARD group. HAQ score signiﬁ  cantly higher in group Ia compared with group Ib (p=0.0353) and 
signiﬁ  cantly higher in group Ia compared with group II (p<001).    
  ‡Including one of twins. 
  §Including twins. 
  ¶One because of Down’s syndrome. 
  DAS28, disease activity score in 28 joints; HAQ, Health Assessment Questionnaire; n/N, number of patients with available data/number of women with pregnancy; RA = rheumatoid 
arthritis;  PsA = psoriatic arthritis ;  JIA = juvenile idiopathic arthritis ;  AS = ankylosing spondylitis;  SLE = Systemic Lupus  Erythematosus.   
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or neonatal illnesses.    9        10        14        15    Data from OTIS, published only 
in abstract form, show that the spontaneous abortion rate was 
7.4% in patients exposed to ADA during the ﬁ  rst  trimester 
and 6.1% in the RA comparison group. These percentages are 
lower than we found in our study population, but no informa-
tion regarding DMARD intake at conception and general disease 
activity was provided for the OTIS population.    16    
  Both MTX and LEF are ‘X’ category drugs. There is a rec-
ognised association between high-dose MTX and spontane-
ous abortion. A recent systematic review found that 23% of 
pregnancies exposed to MTX in the ﬁ  rst trimester resulted 
in spontaneous abortion and 5% of pregnancies resulted in 
reported minor neonatal malformations.    17    In our study, 20 
patients became pregnant while receiving ‘X’ class drugs. It 
is not known whether they were informed about the detri-
mental effects of these drugs, although we do know that a 
few patients became pregnant while using oral contracep-
tives which suggests that these were unplanned pregnancies. 
However, it cannot be concluded that the concurrent use of 
MTX and/or LEF is the only explanation for this increased rate 
of spontaneous abortion, as the rate of spontaneous abortion 
in women exposed to anti-TNF therapy at conception without 
these drugs was also higher than in those previously or never 
exposed to anti-TNF agents. There are data to suggest that 
women with severe RA may have an unfavourable pregnancy 
outcome, and those patients unable to discontinue anti-TNF 
therapies may be those with the most severe disease.    18        19    We 
did not collect data on disease activity at time of conception. 
It is thus important to weigh the impact of disease severity 
on pregnancy outcome and the results found in our study 
with regard to the somewhat increased risk of spontaneous 
abortions in patients receiving anti-TNF agents at conception. 
Despite the exposure of anti-TNF therapy at conception, few 
patients opted for termination. Compared with the termina-
tion rate of 12.9% in women aged 30–34 years in the gen-
eral population of England and Wales (ie, the percentage of 
pregnancies resulting in one or more live births or a stillbirth 
or legal abortion that were terminated by abortion),    20    the ter-
mination rate was higher in those exposed to anti-TNF ther-
apy plus MTX or LEF at conception (19%) but lower in those 
exposed to anti-TNF agents alone (8%). 
  Data on drug safety during pregnancy are largely restricted 
to the cumulative experience of patients and physicians and 
often limited to case reports. One of the biggest challenges in 
obtaining safety data is ensuring that outcomes in all exposed 
patients are recorded, not just those with particularly good or 
bad outcomes. The BSRBR, through the systematic follow-up 
of patients, has captured all pregnancy outcomes as they have 
occurred since the study started in 2001, including information 
on terminations, spontaneous abortions as well as pregnancy 
complications. This may also in part explain the higher rate of 
spontaneous abortion observed in this study compared with 
previous reports. We were also able to compare the pregnancy 
outcomes of patients exposed to anti-TNF therapy before or at 
conception with a control group of patients with RA who were 
never exposed to anti-TNF therapy. However, the number of 
recorded pregnancies in this control group was small.   
  CONCLUSION 
  The results of this current study, one of the largest detailed pro-
spective studies to date, suggest that treatment with anti-TNF 
therapy at the time of conception may be associated with an 
increased risk of spontaneous abortion, but the role of disease 
46/59 (78%) in group II; 10/10 (100%) live births were reported 
in the nb-DMARD group. In two of the three twin pregnan-
cies (one in group I and one in group II), one of the fetuses died 
in utero and one was delivered at/near term (  table 1  ). The rate 
of spontaneous abortion was highest among patients exposed 
to anti-TNF at the time of conception (group I): overall 19/71 
(27%); with MTX/LEF 7/21 (33%); without MTX/LEF 12/50 
(24%). This compared with 10/59 spontaneous abortions (17% 
of pregnancies) in those with prior exposure to anti-TNF agents 
(group II) and 1/10 spontaneous abortion (10% of pregnancies) of 
those never exposed to anti-TNF (group III). In total there were 
10 terminations (4 in group Ia, 4 in group Ib and 2 in group  II). 
Of the 42 live births or 22 spontaneous abortions/intrauterine 
or neonatal deaths in women who were receiving anti-TNF 
therapy at the time of conception (group I), 33/42 (79%) and 
18/22 (82%), respectively, discontinued anti-TNF therapy dur-
ing the ﬁ  rst trimester, 5/42 (12%) and 0 (0%) during the sec-
ond trimester and 4/42 (9%) and 1/22 (5%) received anti-TNF 
therapy throughout their pregnancy. No data on anti-TNF expo-
sure during pregnancy was available for 0 and 3 pregnancies, 
respectively. In those patients with prior exposure to anti-TNF, 
the length of time since the last dose of anti-TNF therapy did not 
differ between those with a live birth and those who miscarried 
(median 7.1 months (IQR 4.4–13.2) vs median 5.7 months (IQR 
0.1–10.4); p=0.275).   
  Pregnancy  complications 
  Of 88 live births in the anti-TNF groups, 19 babies (22%) were 
born prematurely (11/42 (26%) in group I and 8/46 (17%) in 
group II) compared with 2/10 (20%) in the nb-DMARD group. 
One full-term baby had a low birth weight. Four fetuses died in 
utero (two in group Ib and two in group II), including two single 
fetuses in two twin pregnancies. One neonatal death 27 h after 
delivery was reported in a patient who received ETA during the 
ﬁ  rst trimester. The cause of death was perinatal hypoxia. There 
were four reports of congenital malformations, two in group 
Ib (congenital dislocation of the hip and pyloric stenosis) and 
two in group II (winking jaw syndrome and strawberry birth 
mark).        
  DISCUSSION 
  Our study presents the results of the largest detailed prospec-
tive collection of pregnancy outcomes in women with arthri-
tis-related diseases exposed to anti-TNF therapy. In our study 
population a potential signal of an increased spontaneous abor-
tion rate was observed in women exposed to anti-TNF thera-
pies at conception, although this was most evident in those also 
receiving MTX or LEF (33%). Two general population-based 
studies found a clinical spontaneous abortion rate of around 
12%,    4        5    although the actual rate may be higher (~25%) if clini-
cally undetectable pregnancies are also included.    6    
  To put these results into context with the evidence currently 
available, it is important to compare our ﬁ  ndings with those pub-
lished in previous reports (see table in online supplement).    7     –      15    Of 
the known outcomes in pregnancies in cohort studies including 
any patients exposed to anti-TNF agents before or during preg-
nancy, the spontaneous abortion rate ranged from 0% to 14%.    15    
In one study, including data from a survey of US rheumatolo-
gists    8   , one spontaneous abortion occurred in a patient using ETA 
in combination with MTX at the time of conception. Across all 
studies, 31 terminations were reported.    7     –      9        12        14        15    One pregnancy 
was terminated because of concomitant MTX use at the time 
of conception.    7    Eleven babies were born with complications 
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severity and other antirheumatic treatment cannot be excluded. 
Although the collected results to date have been promising with 
few reports of congenital malformations, no ﬁ  rm conclusions 
can be drawn about the safety of anti-TNF therapy during preg-
nancy and, without further evidence, guidelines which suggest 
these drugs should be avoided at the time of conception must 
remain.       
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